Personalized medicine continued its growth over the past year and became one of the most talked about topics in the life sciences industry.
Voyage to Mainstream
Personalized medicine here to stay after massive uptick in 2021 approvals.
Milestones and Momentum: Assessing Advancements in Personalized Medicine
The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.
Gene Therapy on the Verge of Taking Its Next Evolutionary Step
The shift from (ultra) rare to prevalent diseases calls for new vector manufacturing technologies.
Next-Gen Partnerships: The Ascent of Advanced Therapies
With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.
One to Watch: China’s Cell and Gene Therapies Industry
Exploring the market’s emergence on the global stage.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.